Technology Bundle ID

Diagnostic Antigens for the Identification of Latent Tuberculosis Infection

Linked ID
Lead Inventors
Frederick Quinn (CDC)
Kristin Birkness (CDC)
Manon Deslauriers (CDC)
Peter King (CDC)
Development Stages
Pre-clinical (in vivo)
Development Status
  • In vitro data available
  • In vivo data available (human)
CDC researchers have developed technology for sero-diagnosis of typically symptomless latent stage tuberculosis disease, posing a threat to individuals under immunosuppressive or anti-inflammatory therapies. Specifically, this diagnostic approach exploits M. tuberculosis secreted latency specific antigens, such as alpha-crystallin, in the blood or urine of patients. This type of test could easily be developed into an inexpensive dip-stick format with high specificity (no cross-reactivity with other mycobacteria), rapidity, and sensitivity (fewer bacteria needed for a positive identification). Because secreted antigens are recognized more readily by the immune system, serum-derived antibodies to these antigens can correspondingly be used for diagnostic or research use.
Commercial Applications
  • Development of a latent tuberculosis diagnostic
  • Improvements to current diagnostics
  • Public health/tuberculosis monitoring programs
  • Screening elderly patients before beginning anti-inflammatory and/or anti-arthritis therapy
Competitive Advantages
  • Rapid and inexpensive diagnostic for latent stage tuberculosis
  • Specific for latent form, unlike current IGRA/TST diagnostics
  • Easily developed as a cost effective dip-stick test
  • Provides high specificity (no cross-reactivity with other mycobacteria) and sensitivity (fewer bacteria needed for a positive identification)

Request More Info

Licensing Contact: